Department of Medicine;
New York Methodist Hospital;
Division of Hematology/Oncology;
Department of Medicine;
New York Methodist Hospital;
Molecular; pathogenesis; Temozolomide; Glioblastoma; multiforme; Treatment; resistance; Hypoxia; Recurrent; glioblastoma; multiforme; Bevacizumab;